Jump Financial LLC Makes New $3.85 Million Investment in Glaukos Corporation $GKOS

Key Points

• Jump Financial LLC has acquired 39,142 shares of Glaukos Corporation, valued at approximately $3.85 million, representing about 0.07% ownership in the company.
• Glaukos reported a revenue increase of 29.7% year-over-year, with quarterly earnings per share surpassing estimates at ($0.24), compared to a loss of ($0.52) during the same quarter last year.
• Analysts have mixed ratings on Glaukos, with a consensus rating of "Moderate Buy" and a target price of $127.42, despite recent adjustments that lowered some target prices.

Jump Financial LLC acquired a new position in Glaukos Corporation (NYSE:GKOS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 39,142 shares of the medical instruments supplier's stock, valued at approximately $3,852,000. Jump Financial LLC owned approximately 0.07% of Glaukos at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of GKOS. Dimensional Fund Advisors LP boosted its position in Glaukos by 9.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 312,314 shares of the medical instruments supplier's stock worth $46,828,000 after purchasing an additional 26,540 shares in the last quarter. Stifel Financial Corp boosted its position in Glaukos by 2.6% in the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock worth $651,000 after purchasing an additional 111 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Glaukos by 13.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 35,182 shares of the medical instruments supplier's stock worth $5,276,000 after purchasing an additional 4,227 shares in the last quarter. Coldstream Capital Management Inc. purchased a new stake in Glaukos in the 4th quarter worth approximately $208,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Glaukos in the 4th quarter worth approximately $1,903,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GKOS. Zacks Research downgraded Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. William Blair raised Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Stephens reduced their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. BTIG Research reaffirmed a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. Finally, Morgan Stanley reduced their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $127.42.

Glaukos Price Performance

NYSE GKOS traded down $0.70 during mid-day trading on Friday, hitting $95.86. The stock had a trading volume of 488,453 shares, compared to its average volume of 846,228. The firm's 50 day moving average is $95.62 and its 200 day moving average is $99.48. Glaukos Corporation has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The stock has a market capitalization of $5.50 billion, a price-to-earnings ratio of -58.10 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same period in the prior year, the company earned ($0.52) EPS. The firm's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.